|Bid||1.1100 x 1800|
|Ask||1.1200 x 36100|
|Day's Range||1.0500 - 1.1700|
|52 Week Range||0.2700 - 2.3400|
|Beta (5Y Monthly)||1.42|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
U.S. Patent and Trademark Office has allowed a patent to one of the patent applications by Adamis Pharmaceuticals Corp (NASDAQ: ADMP) related to its ZIMHI high-dose naloxone injection product candidate, intended for opioid overdose. The allowed claims comprise a naloxone composition at a dose greater than or equal to five milligrams configured for administration as an injection. "Our 5 mg dose of naloxone delivered by intramuscular or subcutaneous injection has demonstrated significantly higher availability (naloxone in the blood) at 2.5 and 5 minutes (critical period) when compared to the current FDA-approved product", said Dr. Dennis J. Carlo, President, and CEO. Last year, the company received an FDA response letter for the ZIMHI application for opioid overdose, citing Chemistry, Manufacturing, and Controls issues. The company says it looks forward to meeting with the FDA to discuss the responses submitted to the agency's response letter for ZIMHI. Price Action: ADMP stock is down 7.01% at $1.46 in market trading hours on last check Wednesday. See more from BenzingaClick here for options trades from BenzingaNascent Biotech Gains On Encouraging Pritumumab Data From Preclinical StudiesSalarius Moves Forward With Seclidemstat Study In Soft Tissue Cancer; Shares Spike© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Fluidigm (NASDAQ:FLDM) stock is soaring higher on Friday following an update for its novel coronavirus test. Source: Shutterstock.com According to the Fluidigm news release, the company has received the CE-IVD mark needed to commercially sell its test in Europe. This will allow for patients that may be suffering from the coronavirus to be tested without a nasal swab. Instead of a nasal swab, Fluidigm’s Advanta Dx SARS-CoV-2 RT-PCR Assay uses saliva to check for the coronavirus. That’s easier than a nasal test and comes with a comparable level of accuracy.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chris Linthwaite, president and CEO of Fluidigm, said this about the news boosting FLDM stock up today. “Since introduction of our saliva-based COVID-19 testing solution in the United States, we have seen tremendous interest in our testing technology, and we are gratified by the opportunity to offer one of the first saliva-based COVID-19 tests to be widely available in Europe, where the total addressable market for COVID-19 testing, based on third-party and company estimates, is $5 billion to $7 billion in 2021.” The update concerning the coronavirus test caught the interest of investors today. FLDM stock has traded nearly 5 million shares as of this writing. To put that in perspective, the stock’s daily average trading volume is 1.97 million shares. 7 Great Sub-$20 Stocks to Buy After Inauguration Day Coronavirus news continues to be a catalyst for positive stock movement. Just earlier this week Adamis Pharma (NASDAQ:ADMP) saw a massive jump in its stock after revealing plans to treat symptoms of the virus with one of its medications. FLDM stock was up 15.9% as of Friday morning. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner It doesn’t matter if you have $500 in savings or $5 million. Do this now. The post FLDM Stock Alert: Why Fluidigm Shares Are Shooting Higher Today appeared first on InvestorPlace.
Adamis Pharma (NASDAQ:ADMP) stock is taking off on Friday after a week of positive news for the company. Source: Bukhta Yurii / Shutterstock.com Here’s what investors need to know about ADMP stock rising today. The latest news concerning Adamis Pharma is that its SYMJEPI Injection products are being offered at a special price to members of the Walgreens Prescription Savings Club program. These are the company’s epinephrine injections used in emergencies to treat people suffering from an allergic reaction. Walgreens Boots Alliance (NASDAQ:WBA) is offering the epinephrine injections at a price of two for $99. That’s not only the cheapest price for this type of drug in the savings program but is the cheapest on the market. Dr. Dennis J. Carlo, president and CEO of Adamis Pharma, said this about the news boosting ADMP stock today.InvestorPlace - Stock Market News, Stock Advice & Trading Tips “We are very excited Walgreens has added SYMJEPI through its Prescription Savings Club and feel this program will avail this potentially life-saving medication to the patients that need it most. Adamis remains committed to making SYMJEPI the most affordable epinephrine product available to patients.” 7 Great Sub-$20 Stocks to Buy After Inauguration Day ADMP stock was also up earlier this week on treatment news for the novel coronavirus. The company is seeking to test out its Tempol for treating patients affected by the virus. This isn’t a vaccine and instead would treat the symptoms of the coronavirus. Adamis Pharma’s reasoning is that treatments outside of vaccines need to continue as the coronavirus continues to mutate. ADMP stock was up 52.4% as of Friday morning. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner It doesn’t matter if you have $500 in savings or $5 million. Do this now. The post ADMP Stock: 4 Things to Know About Adamis Pharma Today as Shares Rocket Again appeared first on InvestorPlace.